Equities

Medistim ASA

Medistim ASA

Actions
Health CareMedical Equipment and Services
  • Price (NOK)148.00
  • Today's Change7.00 / 4.96%
  • Shares traded7.46k
  • 1 Year change-27.80%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Medistim ASA is a Norway-based company engaged in the provision of medical equipment and technology. It develops, manufactures and distributes medical devices that measure blood flow and visualize atherosclerosis, and thereby help improve the outcome of cardiac and vascular surgery. The Company provides Transit Time Flow Measurement (TTFM) and ultrasound imaging to the global market to enable medical professionals to reduce risk and enhance quality of cardiac, vascular and transplant surgery. Medistim’s activities are divided into two business units: Own Products Category and Third-Party Products Category. Furthermore, the Company has several subsidiaries, including Medistim USA Inc, Medistim Norge AS and Medistim Japan KK.

  • Revenue in NOK (TTM)547.08m
  • Net income in NOK101.64m
  • Incorporated1995
  • Employees152.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nordhealth As506.63m-95.80m1.68bn403.00--3.3257.593.32-1.23-1.236.5011.210.475--9.491,282,595.00-8.98---10.01--85.89---18.91------0.00--18.60--21.96------
Genovis AB129.86m27.94m1.78bn32.0063.808.0145.4613.730.42630.42631.983.390.4239----3,506,189.009.1218.569.8021.4564.6965.5121.5123.88----0.25550.0054.5435.56449.56--47.59--
Stille AB487.91m50.91m1.86bn151.0032.712.7724.803.826.336.3360.9474.850.69782.108.494,598,368.007.287.038.708.1949.1743.9310.439.851.127.410.0021.9819.7016.78-2.485.3423.62--
Detection Technology Oyj-1.16tn-1.16tn2.36bn464.00--2.76----------5.03----------9.34--11.96--47.44--8.223.39--0.0053.455.292.027.55-18.03-14.88-9.55
BICO Group AB2.25bn-787.58m2.39bn828.00--0.8285--1.06-11.15-15.2031.9241.790.36022.154.472,547,964.00-12.62---14.44--55.70---35.03--2.23-0.57050.397--6.09---1,889.33------
Medistim ASA547.08m101.64m2.59bn152.0025.416.3720.424.735.555.5529.8722.121.130.74617.483,599,204.0021.0522.9325.5328.5279.1278.2518.5820.642.75--0.018175.257.0010.06-8.9112.720.03314.87
Data as of Nov 22 2024. Currency figures normalised to Medistim ASA's reporting currency: Norwegian Krone NOK

Institutional shareholders

51.64%Per cent of shares held by top holders
HolderShares% Held
Aeternum Management ASas of 27 Sep 20231.90m10.36%
SEB Investment Management AB (Denmark)as of 31 Oct 20241.37m7.48%
ODIN Forvaltning ASas of 14 Apr 20231.20m6.54%
Swedbank Robur Fonder ABas of 31 Oct 20241.11m6.03%
Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 29 Sep 20231.01m5.49%
Invesco Advisers, Inc.as of 30 Sep 2024910.00k4.96%
Fidelity Management & Research Co. LLCas of 30 Sep 2024627.55k3.42%
ODIN Forvaltning AS (Sweden)as of 14 Apr 2023600.00k3.27%
Skandinaviska Enskilda Banken AB (Denmark)as of 31 Oct 2024401.28k2.19%
Holberg Fondsforvaltning ASas of 14 Apr 2023346.75k1.89%
More ▼
Data from 31 Dec 2023 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.